Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

Expert Review of Clinical Pharmacology

Volumn 8, Issue 1, 2014, Pages 77-94

  Godman, Brian ^a,b,c   Malmström, Rickard E ^a   Diogene, Eduardo ^d   Gray, Andy ^e   Jayathissa, Sisira ^f   Timoney, Angela ^b,g   Acurcio, Francisco ^h   Alkan, Ali ⁱ   Brzezinska, Anna ^j   Bucsics, Anna ^k   Campbell, Stephen M ^l   Czeczot, Jadwiga ⁱ   De Bruyn, Winnie ^m   Eriksson, Irene ⁿ   Yusof, Faridah Aryani Md ^o   Finlayson, Alexander E ^p   Fürst, Jurij ^q   Garuoliene, Kristina ^r,s   Guerra Júnior, Augusto ^h   Gulbinovič, Jolanta ^r,t   Jan, Saira ^u,v   Joppi, Roberta ^w   Kalaba, Marija ^x   Magnisson, Einar ^y   McCullagh, Laura ^z   Miikkulainen, Kaisa ^aa   Ofierska Sujkowska, Gabriela ^j   Pedersen, Hanne Bak ^ab   Selke, Gisbert ^ac   Sermet, Catherine ^ad   Spillane, Susan ^ae   Supian, Azuwana ^o   Truter, Ilse ^af   Vlahović Palčevski, Vera ^ag   Vien, Low Ee ^o   Vural, Elif H ⁱ   Wale, Janet ^f   Władysiuk, Magdałene ^ah   Zeng, Wenjie ^ai   Gustafsson, Lars L ^a   more..

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e UNIVERSITY OF KWAZULU NATAL   (South Africa)

^f University of KwaZulu Natal ^*  (Australia)

^g NHS LOTHIAN   (United Kingdom)

^h FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

ⁱ MINISTRY OF HEALTH   (Turkey)

^j Agency for Health Technology Assessment in Poland   (Poland)

^k UNIVERSITY OF VIENNA   (Austria)

^l UNIVERSITY OF MANCHESTER   (United Kingdom)

^m UTRECHT UNIVERSITY   (Netherlands)

ⁿ STOCKHOLM COUNTY COUNCIL   (Sweden)

^o MINISTRY OF HEALTH   (Malaysia)

^p UNIVERSITY OF OXFORD   (United Kingdom)

^q Health Insurance Institute   (Slovenia)

^r VILNIUS UNIVERSITY   (Lithuania)

^s National Health Insurance Fund   (Lithuania)

^t State Medicine Control Agency of Lithuania   (Lithuania)

^u RUTGERS UNIVERSITY   (United States)

^v HORIZON BLUE CROSS BLUE SHIELD OF NEW JERSEY   (United States)

^w Pharmaceutical Drug Department   (Italy)

^x Republic Institute for Health Insurance   (Serbia)

^y Ministry of Health   (Iceland)

^z ST JAMES S HOSPITAL   (Ireland)

^aa KAROLINSKA INSTITUTE   (Sweden)

^ab WHO REGIONAL OFFICE FOR EUROPE   (Denmark)

^ac Wissenschaftliches Institut der AOK WIdO   (Germany)

^ad IRDES   (France)

^ae TRINITY COLLEGE DUBLIN   (Ireland)

^af NELSON MANDELA METROPOLITAN UNIVERSITY   (South Africa)

^ag KBC RIJEKA   (Croatia)

^ah HTA CONSULTING   (Poland)

^ai CHONGQING JIAOTONG UNIVERSITY   (China)

more..

Author keywords

clinical pharmacology; critical drug evaluation; dabigatran; differential pricing; ivacaftor; managed entry agreements; new models; rational use of medicines; sofosbuvir; trastuzumab emtansine

Indexed keywords

ADALIMUMAB; DABIGATRAN; ETANERCEPT; DRUG;

CANCER THERAPY; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG INDUSTRY; DRUG SCREENING; DRUG UTILIZATION; EMBOLISM; FRANCE; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEART ATRIUM FIBRILLATION; HUMAN; MEDICAL DECISION MAKING; MEDICINE; ONCOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); REIMBURSEMENT; REVIEW; RHEUMATOID ARTHRITIS; TRANSPLANTATION; DRUG DEVELOPMENT; DRUG USE; HEALTH CARE DELIVERY; PROCEDURES;

CLINICAL TRIALS, PHASE III AS TOPIC; DELIVERY OF HEALTH CARE; DRUG DISCOVERY; DRUG INDUSTRY; DRUG UTILIZATION REVIEW; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 84916931880     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2015.990380     Document Type: Review

References (170)

1. Babar ZU, Francis S. Identifying priority medicines policy issues for New Zealand: a general inductive study. BMJ Open 2014; 4(5):e004415
2. Drews J. Drug discovery: a historical perspective. Science 2000;287(5460):1960-4
3. Lichtenberg F. Pharmaceutical innovation and longevity growth in 30 developing and high-income countries, 2000-2009. Health Policy Technol 2014;3:36-58
4. Thomas Hofmarcher, Bengt Jönsson, Nils Wilking. Access to high-quality oncology care across europe. Available from: www.ihe. se/getfile.aspx?id=23042014
5. Jönsson B, Ramsey S, Wilking N. Cost effectiveness in practice and its effect on clinical outcomes. J Cancer Policy 2014;2: 12-21
6. Brennan T, Shrank W. New expensive treatments for hepatitis C infection. JAMA 2014;312(6):593-4
7. News and analysis. Costly cancer care. JAMA 2014;312(6):591
8. Kmietowicz Z. NICE says drug for metastatic breast cancer is unaffordable for NHS. BMJ 2014;348:g2888
9. Simoens S, Picavet E, Dooms M, et al. Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum. Appl Health Econ Health Policy 2013; 11(1):1-3 . Discusses key issues surrounding the cost-effectiveness of orphan drugs and the implications for health policy.
10. Garattini S, Bertele V, Godman B, et al. Enhancing the rational use of new medicines across European health care systems. Eur J Clin Pharmacol 2008;64(12): 1137-8
11. Mousnad MA, Shafie AA, Ibrahim MI. Systematic review of factors affecting pharmaceutical expenditures. Health Policy 2014;116(2-3):137-46
12. Godman B, Petzold M, Bennett K, et al. Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources?: findings from across Europe and their implications. BMC Med 2014;12(1):98
13. Godman B, Malmstrom RE, Diogene E, et al. Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. Front Pharmacol 2014;5:109 .. Discusses new models to optimize the managed entry of new medicines building on health authority activities with dabigatran.
14. Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA 2014;312(6):631-40
15. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87(1):4-14
16. Kaplan W, Wirtz V, Mantel-Teeuwisse A, et al. Priority Medicines for Europe and the World 2013 Update Report. 2013. Available from: www.who.int/medicines/ areas/priority-medicines/ MasterDocJune28-FINAL-Web.pdf?ua=1
17. Lam B, Henry L, Younossi Z. Sofosbuvir (Sovaldi) for the treatment of hepatitis C. Expert Rev Clin Pharmacol 2014;7(5): 555-66
18. Hillner BE, Smith TJ. Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. J Clin Oncol 2009;27(13):2111-13
19. Godman B, Finlayson AE, Cheema PK, et al. Personalizing health care: feasibility and future implications. BMC Med 2013;11:179
20. O'Sullivan BP, Orenstein DM, Milla CE. Pricing for orphan drugs: will the market bear what society cannot? JAMA 2013; 310(13):1343-4
21. Evaluate Pharma. Surveying Tomorrow's BioPharma Landscape. The NASDAQ Biotech Index Up Close 2012. Available from: http://info.evaluatepharma.com/rs/ evaluatepharmaltd/images/ EvaluatePharma-NBI-Up-Close-2012.pdf
22. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121(22):4439-42
23. Cohen P, Felix A. Are payers treating orphan drugs differently? J Market Access Health Policy 2014.2:23513. Available from: http://dx.doi.org/10.3402/jmahp.v2
24. Rodwin MA. Introduction: institutional corruption and the pharmaceutical policy. J Law Med Ethics 2013;41(3):544-52
25. Ozieranski P, McKee M, King L. Pharmaceutical lobbying under postcommunism: universal or country-specific methods of securing state drug reimbursement in Poland? Health Econ Policy Law 2012;7(2):175-95
26. Mello MM, Abiola S, Colgrove J. Pharmaceutical companies' role in state vaccination policymaking: the case of human papillomavirus vaccination. Am J Public Health 2012;102(5):893-8
27. Luo J, Oliveira MA, Ramos MB, et al. Antiretroviral drug expenditure, pricing and judicial demand: an analysis of federal procurement data in Brazil from 2004-2011. BMC Public Health 2014;14:367
28. Lexchin J, Kohler JC. The danger of imperfect regulation: oxyContin use in the United States and Canada. Int J Risk Saf Med 2011;23(4):233-40
29. Spurling GK, Mansfield PR, Montgomery BD, et al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review. PLoS Med 2010;7(10): e1000352
30. Baumgärtel C, Godman B, Malmström R, et al. What lessons can be learned from the launch of generic clopidogrel? GaBI J 2012; 1(2):58-68
31. Light DW, Lexchin J, Darrow JJ. Institutional corruption of pharmaceuticals and the myth of safe and effective drugs. J Law Med Ethics 2013;41(3):590-600
32. Neuman J, Korenstein D, Ross JS, Keyhani S. Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study. BMJ 2011;343:d5621
33. Davis C, Abraham J. Is there a cure for corporate crime in the drug industry? BMJ 2013;346:f755
34. Gagnon MA. Corruption of pharmaceutical markets: addressing the misalignment of financial incentives and public health. J Law Med Ethics 2013;41(3):571-80
35. Fisk M, Feeley J, Voreacos D. J&J Said to Agree to $2.2 Billion Drug Marketing Accord. 2012. Available from: wwwbloombergcom/news/2012-06-11/j-jsaid- to-pay-2-2-billion-to-end-risperdal-salesprobe. html
36. Department of Justice (US). Department of Justice Settlement agreement between United States and AstraZeneca. 2010. Available from: www.justice.gov/usao/pae/ Pharma-Device/astrazeneca- settlementagreement.pdf
37. Godman B, Bucsics A, Burkhardt T, et al. Insight into recent reforms and initiatives in Austria: implications for key stakeholders. Expert Rev Pharmacoecon Outcomes Res 2008;8(4):357-71
38. New drugs and indications in 2011. France is better focused on patients' interests after the Mediator scandal, but stagnation elsewhere. Prescrire Int 2012;21(126):106-7
39. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: justum Pretium-the just price. J Clin Oncol 2013;31(28):3600-4 .. Discusses concerns with the high prices of cancer medicines, especially given limited health gain of many of these and presents potential ways forward for valuing them in the future.
40. Scottish Medicines Consortium. sofosbuvir 400mg tablet (Sovaldi). SMC No. (964/14). Available from: www.scottishmedicines.org.uk/files/advice/M-Scottish-Medicine-Consortium-Web-Data-Audit-advice-Advice-by-Year-2014-No.6-June-2014-sofosbuvir-Sovaldi-FINAL-May-2014-for-website.pdf
41. Malmstrom RE, Godman BB, Diogene E, et al. Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol 2013;4:39
42. van Vollenhoven RF, Askling J. Rheumatoid arthritis registries in Sweden. Clin Exp Rheumatol 2005;23(5 Suppl 39): S195-200
43. Campbell SM, Godman B, Diogene E, et al. Quality indicators as a tool in improving the introduction of new medicines. Basic Clin Pharmacol Toxicol 2014. [Epub ahead of print] . Discusses a proposed methodology for developing quality indicators for new medicines in the future together with potential examples.
44. Gorokhovich LE, Chalkidou K, Shankar R. Improving access to innovative medicines in emerging markets: evidence and diplomacy as alternatives to the unsustainable status quo. J Health Diplomacy 2013;1(1):1-19
45. Faden L, Vialle-Valentin C, Ross-Degnan D, Wagner A. Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: a systematic review of current evidence. Health Policy 2011;100(2-3): 134-43
46. Sheppard A. Generic Medicines: Essential contributors to the long-term health of society - Sector sustainability challenges in Europe. Available from: www.imshealth. com/imshealth/Global/Content/Document/ Market-Measurement-TL/ Generic-Medicines-GA.pdf
47. Babar ZU, Kan SW, Scahill S. Interventions promoting the acceptance and uptake of generic medicines: a narrative review of the literature. Health Policy 2014;117(3): 285-96
48. Kaplan WA, Ritz LS, Vitello M, Wirtz VJ. Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000-2010. Health Policy 2012;106(3):211-24
49. Moon JC, Godman B, Petzold M, et al. Different initiatives across Europe to enhance losartan utilization post generics: impact and implications. Front Pharmacol 2014;5:219
50. Godman B, Wettermark B, van Woerkom M, et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Front Pharmacol 2014;5:106
51. Hassali MA, Alrasheedy A, McLachlan A, et al. The experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine use. Saudi Med J 2014. [In Press] Available from: http://ac.els-cdn.com/ S131901641300128X/1-s2.0-SX-main.pdf?-tid=e8de644e-f7d0-11e3-925d-00000 aacb35f&acdnat=1403196418-7987f3f513f2ef578bb8a8372b612f1a
52. Godman B, Acurcio F, Guerra Junior AA, et al. Initiatives among authorities to improve the quality and efficiency of prescribing and the implications. J Pharma Care Health Sys 2014;1(3):1-15
53. Garner S, Littlejohns P. Do NICE's recommendations for disinvestment add up? BMJ 2011;343:349-51
54. Pichetti S, Sorasith C, Sermet C. Analysis of the impact of removing mucolytics and expectorants from the list of reimbursable drugs on prescription rates: a time-series analysis for France 1998-2010. Health Policy 2011;102(2-3):159-69
55. Elshaug AG, Watt AM, Mundy L, Willis CD. Over 150 potentially low-value health care practices: an Australian study. Med J Aust 2012;197(10):556-60
56. Nuti S, Vainieri M, Bonini A. Disinvestment for re-allocation: a process to identify priorities in healthcare. Health Policy 2010;95(2-3):137-43
57. Schmucker C, Ehlken C, Agostini HT, et al. A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus gold standard. PLoS One 2012;7(8): e42701
58. Silverman E. How Italy Saves Money: Paying For Off-Label Use of Avastin. Available from: http://blogs.wsj.com/ pharmalot/2014/06/11/how-italy-savesmoney- paying-for-off-label-use-of-avastin/
59. Jolly D. Italy Fines Novartis and Roche in Collusion Case. 2014. Available from: www. nytimes.com/2014/03/06/business/ international/italy-fines-novartis-and-rochein-collusion-case.html?-r=0
60. Vitry AI, Shin NH, Vitre P. Assessment of the therapeutic value of new medicines marketed in Australia. J Pharm Policy Pract 2013;6:2
61. Van Wilder P, Dupont A. Introducing evidence-based medicine in reimbursement procedures: does it affect the outcome? Value Health 2008;11(4):784-7 . Presents figures demonstrating the limited level of innovation of most new medicines.
62. Light DW, Lexchin JR. Pharmaceutical research and development: what do we get for all that money? BMJ 2012;345:e4348
63. Cohen FJ. Macro trends in pharmaceutical innovation. Nat Rev Drug Discov 2005; 4(1):78-84
64. Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009;101(15):1044-8
65. Barbui C, Violante A, Garattini S. Does placebo help establish equivalence in trials of new antidepressants? Eur Psychiatry 2000;15(4):268-73
66. Garattini S, Bertele V, Banzi R. Placebo? No thanks, it might be bad for me!. Eur J Clin Pharmacol 2013;69(3):711-14
67. Henshall C, Sansom L, Eichler H-G, et al. Understanding the role and evidence expectations of health technology assessment and coverage/payer bodies: what are they looking for, and how and why does this differ from what regulators require? Ther Innov Regul Sci 2014;48(3):341-6
68. Mullard A. 2011 FDA drug approvals. Nat Reviews Drug Discov 2012;11(2):91-4
69. Kelly RJ, Smith TJ. Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. Lancet Oncol 2014;15(3):e112-e8
70. Uyl-de Groot CA, de Vries E, Verweij J, Sullivan R. Dispelling the myths around cancer care delivery: it's not all about costs. J Cancer Policy 2014;2:22-9
71. Lambert JM, Chari RV. Ado-trastuzumab Emtansine (T-DM1): an Antibody-Drug Conjugate (ADC) for HER2-Positive Breast Cancer. J Med Chem 2014;57(16):6949-64
72. Corrigan PA, Cicci TA, Auten JJ, Lowe DK. Ado-trastuzumab Emtansine: A HER2-positive targeted antibody-drug conjugate. Ann Pharmacother 2014;48(11): 1484-93
73. NCPE. Trastuzumab emtansine (Kadcyla) - reimbursement not recommended. Available from: http://www.ncpe.ie/wp-content/ uploads/2013/10/Trastuzumab-emtansinesummary. pdf
74. Duerden M. Affording expensive new drugs. Prescriber 2014;8
75. Barrett A, Roques T, Small M, Smith RD. How much will Herceptin really cost? BMJ 2006;333(7578):1118-20
76. Brogan DM, Mossialos E. Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model. Global Health 2013;9:58
77. Roland D. Why is Roche's new breast cancer drug so expensive? Available from: www.telegraph.co.uk/finance/newsbysector/ pharmaceuticalsandchemicals/11021272/ Why-is-Roches-new-breast-cancer-drug-soexpensive. html
78. NICE News and Features. Pressure grows on Roche to lower breast cancer drug price. Available from: https://www.nice.org.uk/ News/Article/pressure-grows-on-roche-tolower- breast-cancer-drug-price2014
79. Roche. Annual Report. Available from: www.google.co.uk/url?sa=t&rct=j& q=&esrc=s&source=web&cd=1& ved=0CCEQFjAA&url=http%3A%2F% 2Fwww.roche.com%2Fgb13e.pdf&ei= JA0EVJqrNdPZavLDgJAG&usg= AFQjCNF-VWJBImTwunCSU50eqb- OtDfvRA&bvm=bv.74115972,d.d2s2013
80. Woerkom M, Piepenbrink H, Godman B, et al. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. J Comp Eff Res 2012;1(6):527-38
81. Godman B, Wettermark B, Hoffmann M, et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Res 2009;9(1): 65-83
82. Godman B, Bishop I, Finlayson AE, et al. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Rev Pharmacoecon Outcomes Res 2013;13(4):469-82
83. Godman B, Gustafsson LL. A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing. Appl Health Econ Health Policy 2013;11(1):79-82
84. Gentile I, Borgia G. Ledipasvir/Sofosbuvir administration achieves very high rate of viral clearance in patients with HCV genotype 1 infection without cirrhosis, regardless of ribavirin co-administration or length of treatment. Evid Based Med 2014
85. Yau AH, Yoshida EM. Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: A concise review. Can J Gastroenterol Hepatol 2014;28(8):445-51
86. Zawawi M. Malaysian Society of Gastroenterology and Hepatology. MANAGEMENT OF HEPATITIS C 2014. Available from: www.msgh.org.my/ resources/managementhepatitisc.htm
87. MSF Access Campaign (Access Campaign). Diagnosis and Treatment of Hepatitis C: a technical landscape. 2014. Available from: www.msfaccess.org/sites/default/files/ MSF-assets/HepC/Docs/MSF%20HCV% landscape.pdf
88. Appleby J. Who Should Get Pricey Hepatitis C Drugs? 2014. Available from: www.kaiserhealthnews.org/stories/2014/may/ 05/sovaldi-who-should-get-pricey-drug.aspx? utm-campaign=khn%3a+daily+health +policy+report&utm-source=hs-email& utm-medium=email&utm-content= 12687408&-hsenc=p2anqtz-80dq0zkyq 2cmdwwi2qfttaz29txfzqm-fnpvl7 bczz8ps8h4pu0ssjarxaqkjchr867noeij3yhi6msp3- 9uc2gfpyw&-hsmi=12687408
89. Heitz D. Harvoni takes the sting out of hepatitis c treatment. healthline news. 2014. Available from: www.healthline.com/healthnews/ harvoni-takes-sting-out-of-hepatitis-ctreatment- 102614
90. Beasley D. UPDATE 2-Gilead third-quarter Sovaldi sales dip, but net profit triples: Reuters. 2014. Available from: www.reuters. com/article/2014/10/28/gilead-sciencesresults- idUSL1N0SN2NY20141028
91. International Diabetes Federation. IDF Diabetes Atlas, 6th edition. Brussels, Belgium. Available from: www.idf.org/sites/default/files/EN-6E-Atlas-Full-0.pdf
92. Majumdar SK, Inzucchi SE. Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy? Endocrine 2013; 44(1):47-58
93. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 2014;383(9922): 1068-83
94. IMS. Spending levels in 2017 on medicine for specific disease areas will differ significantly between developed and pharmerging markets. Spending by Therapy Area in 2017. The Global Use of Medicines: Outlook through 2017 Report by the IMS Institute for Healthcare Informatics. 2014. Available from: www. imshealth.com/deployedfiles/imshealth/ Global/Content/Corporate/IMS%20Health %Institute/Reports/Global-Use-of-Meds-Outlook-2017/Spending-Therapy-Area-.pdf
95. IMS. The global use of medicines: outlook through 2016 - Report by IMS Institute for Healthcare Informatics. Available from: www.imshealth.com/deployedfiles/ims/ Global/Content/Insights/IMS%20Institute% 20for%20Healthcare%20Informatics/Global %20Use%20of%20Meds%202011/ Medicines-Outlook-Through-2016-Report. pdf
96. NICE. The Management of Type 2 Diabetes: NICE Clinical Guideline
97. National Institute for Health and Care Excellence; London: 2009
98. Editorial. Towards better patient care: drugs to avoid. Rev Prescrire 2013;33(352): 138-42
99. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993;329(5):304-9
100. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 2002;25(12):2165-71
101. Michel M, Toumi M. Access to orphan drugs in Europe: current and future issues. Expert Rev Pharmacoecon Outcomes Res 2012;12(1):23-9
102. Picavet E, Morel T, Cassiman D, Simoens S. Shining a light in the black box of orphan drug pricing. Orphanet J Rare Dis 2014;9:62
103. Morel T, Arickx F, Befrits G, et al. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries. Orphanet J Rare Dis 2013;8:198 . Illustrates the growth in managed entry agreements for new medicines across Europe.
104. Dupont AG, Van Wilder PB. Access to orphan drugs despite poor quality of clinical evidence. Br J Clin Pharmacol 2011;71(4): 488-96
105. National Commissioning Board. Clinical Commissioning Policy: ivacaftor for Cystic Fibrosis - Reference : NHSCB/A01/P/b. Available from: www.england.nhs.uk/wpcontent/ uploads/2013/04/a01-p-b.pdf
106. Joppi R, Bertele V, Garattini S. Orphan drug development is not taking off. Br J Clin Pharmacol 2009;67(5):494-502
107. Gemeinsamer Bundesausschuss. Questions and Answers about the Procedure - Are orphan drugs exempt from early assessment? Available from: www.english.g-ba.de/ benefitassessment/information/faq/#32014
108. Joppi R, Bertele V, Garattini S. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur J Clin Pharmacol 2013;69(4):1009-24
109. Process on Corporate Social Responsibility in the Field of Pharmaceuticals - Platform on Access to Medicines in Europe. Working Group on Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA-OMP). 2012. Available from: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/orphans-conlusions-en.pdf
110. Braunlin E, Rosenfeld H, Kampmann C, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme(R)) therapy. J Inherit Metab Dis 2013;36(2):385-94
111. Kaiser J. Personalized medicine. New cystic fibrosis drug offers hope, at a price. Science 2012;335(6069):645
112. Cohen D, Raftery J. Paying twice: questions over high cost of cystic fibrosis drug developed with charitable funding. BMJ 2014;348:g1445
113. European Medicines Agency. Kalydeco - Key Facts. 2014. Available from: www.ema. europa.eu/ema/index.jsp?curl=pages/ medicines/human/medicines/002494/smops/ Positive/human-smop-000701. jsp&mid=WC0b01 ac058001d127&source=home MedSearch&category=human
114. FiercePharma. Vertex Receives European Approval for KALYDECO(TM) (ivacaftor) in Eight Non-G551D Gating Mutations. Available from: www.fiercepharma.com/ press-releases/vertex-receives-europeanapproval- kalydecotm-ivacaftor-eight-nong551d- gati
115. Scottish Medicines Consortium. Ivacaftor 150mg film-coated tablets (Kalydeco) SMC No. (827/12) - Resubmission 2013. Available from: www.scottishmedicines.org. uk/files/advice/ivacaftor-Kalydeco- Resubmission-FINAL-May-2013. doc-for-website.pdf
116. PharmaDispatch; Copays and listings the focus of Senate Estimates 2014. Available from: www.cysticfibrosis.org.au/media/ wysiwyg/CF-Australia/Advocacy/Kalydeco/ PharmaDispatch.pdf
117. Guerra AA Jr, Cesar CC, Cherchiglia ML, et al. Cyclosporine versus tacrolimus in immunosuppressive maintenance regimens in renal transplants in Brazil: survival analysis from 2000 to 2004. Ann Pharmacother 2010;44(1):192-201
118. Larock AS, Mullier F, Sennesael AL, et al. Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study. Ann Pharmacother 2014;48(10): 1258-68
119. Cohen D. Dabigatran: how the drug company withheld important analyses. BMJ 2014;349:g4670
120. Phend C. Monitoring, dose adjustment for pradaxa? 2014. Available from: www. medpagetoday.com/Cardiology/Arrhythmias/ 46901
121. Iannone F, Gremese E, Atzeni F, et al. Long-term retention of tumor necrosis factor-alpha inhibitor therapy in a large Italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol 2012;39(6):1179-84
122. Raaschou P, Simard JF, Holmqvist M, Askling J. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ 2013;346:f1939
123. Nell-Duxneuner V, Schroeder Y, Reichardt B, Bucsics A. The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009 - a retrospective analysis. Int J Clin Pharmacol Ther 2012; 50(12):867-72
124. Spatz I, McGee N. Health Policy Brief: Specialty Pharmaceuticals. Health Affairs 2013;1-4
125. Khan S, Moore JE, Gomes T, et al. The ontario drug policy research network: bridging the gap between research and drug policy. Health policy (Amsterdam, Netherlands) 2014
126. Gustafsson LL, Wettermark B, Godman B, et al. The 'wise list' - a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol 2011;108(4): 224-33
127. Bjorkhem-Bergman L, Andersen-Karlsson E, Laing R, et al. Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. Eur J Clin Pharmacol 2013;69(Suppl 1):73-8 .. Discusses concerns with interface management and potential ways forward based on experiences among European countries.
128. Kardakis T, Tomson G, Wettermark B, et al. The establishment and expansion of an innovative centre for rational pharmacotherapy-determinants and challenges. Int J Health Plann Manage 2013
129. Wonder M. What can be gained from increased early-stage interaction between regulators, payers and the pharmaceutical industry? Expert Rev Pharmacoecon Outcomes Res 2014;14(4):465-7
130. Godman B, Paterson K, Malmstrom RE, et al. Improving the managed entry of new medicines: sharing experiences across Europe. Expert Rev Pharmacoecon Outcomes Res 2012;12(4):439-41
131. Joppi R, Dematte L, Menti AM, et al. The Italian Horizon Scanning Project. Eur J Clin Pharmacol 2009;65(8):775-81
132. Packer C, Fung M, Stevens A. Analyzing 10 years of early awareness and alert activity in the United kingdom. Int J Technol Assess Health Care 2012;28(3):308-14
133. Nachtnebel A, Geiger-Gritsch S, Hintringer K, Wild C. Scanning the horizon: development and implementation of an early awareness system for anticancer drugs in Austria. Health Policy 2012; 104(1):1-11
134. Wild C, Simpson S, Douw K, et al. Information service on new and emerging health technologies: identification and prioritization processes for a European union-wide newsletter. Int J Technol Assess Health Care 2009;25(Suppl 2):48-55
135. Wettermark B, Persson ME, Wilking N, et al. Forecasting drug utilization and expenditure in a metropolitan health region. BMC Health Serv Res 2010;10:128
136. Joppi R, Cinconze E, Mezzalira L, et al. Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: a population-based study. Eur J Intern Med 2013;24(4):318-23
137. Troncoso A, Diogene E. Dabigatran and rivaroxaban prescription for atrial fibrillation in Catalonia, Spain: the need to manage the introduction of new drugs. Eur J Clin Pharmacol 2014;70(2):249-50
138. Fritz JM, Cleland J. Effectiveness versus efficacy: more than a debate over language. J Orthop Sports Phys Ther 2003;33(4): 163-5
139. Wonder M, Backhouse ME, Hornby E. Early scientific advice obtained simultaneously from regulators and payers: findings from a pilot study in Australia. Value Health 2013;16(6):1067-73
140. Gauld R. Ahead of Its Time? Reflecting on New Zealand's Pharmac Following Its 20th Anniversary. Pharmacoeconomics 2014; 32(10):937-42
141. Babar Z-U-D, Vitry A. Differences in Australian and New Zealand medicines funding policies. Aust Health Rev 2014; 38(1):6-15
142. Metcalfe S, Grocott R, Rasiah D. Comment on "Ahead of Its Time? Reflecting on New Zealand's Pharmac Following its 20th Anniversary" : Clarification from PHARMAC: PHARMAC Takes No Particular Distributive Approach (Utilitarian or Otherwise). Pharmaco Economics 2014; 32(10):1031-3
143. Wonder M, Milne R. Access to new medicines in New Zealand compared to Australia. N Z Med J 2011;124(1346): 12-28
144. Kolasa K, Schubert S, Manca A, Hermanowski T. A review of Health Technology Assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland. Health Policy 2011;102(2-3):145-51
145. Moon S, Jambert E, Childs M, von Schoen-Angerer T. A win-win solution?: a critical analysis of tiered pricing to improve access to medicines in developing countries. Global Health 2011;7:39
146. Knowledge Ecology International. Resurrecting the Ghost of Høsbjør Past: Global Fund seeks to establish global framework on tiered pricing enforced by WTO rules. Available at: http://keionline. org/node/1979
147. Baker B. Industry-led tiered-pricing or country-led, real equitable access - the global fund's task force proposal get worse instead of better. Available from: http:// infojustice.org/wp-content/uploads/2014/03/ Baker-Global-Fund-Tiered-Pricing- 03282014.pdf
148. Vogler S, Zimmermann N, Habl C, Mazag J. The role of discounts and loss leaders in medicine procurement in Austrian hospitals - a primary survey of official and actual medicine prices. Cost effectiveness and resource allocation : C/E 2013;11(1):15
149. DeRidder R, Adriaens C, Kleinermans D, et al. Mechanism of coordinated access to orphan drugs. Orphanet J Rare Dis 2012; 7(Suppl 2):A24
150. Garattini S. Time to revisit the orphan drug law. Eur J Clin Pharmacol 2012;68(2):113
151. Schiff GD, Galanter WL, Duhig J, et al. A prescription for improving drug formulary decision making. PLoS Med 2012;9(5):1-7
152. Lima-Dellamora ED, Caetano R, Gustafsson LL, et al. An Analytical Framework for Assessing Drug and Therapeutics Committee Structure and Work Processes in Tertiary Brazilian Hospitals. Basic Clin Pharmacol Toxicol 2014;115(3):268-76
153. Jones MI, Greenfield SM, Bradley CP. Prescribing new drugs: qualitative study of influences on consultants and general practitioners. BMJ 2001;323(7309):378-81
154. Trindade E. [Adoption of new technologies by health services: the challenge of analyzing relevant factors]. Cad Saude Publica 2008; 24(5):951-64
155. Van Wilder PB, Bormans VV, Dupont AG. Relative efficacy and effectiveness assessment of new pharmaceuticals in three EU member states: current practices and outcome agreement between Belgium, the Netherlands and France. Eur J Clin Pharmacol 2013;69(12):2037-43
156. Rosenberg-Yunger ZR, Thorsteinsdottir H, Daar AS, Martin DK. Stakeholder involvement in expensive drug recommendation decisions: an international perspective. Health Policy 2012;105(2-3): 226-35
157. Canadian Partnership Against Cancer and pCODR. How cancer drug funding decisions are made. 2012. Available from: http://www.pcodr.ca/idc/groups/pcodr/ documents/pcodrdocument/pcodr-fundingtutorial. pdf
158. European Commission. Platform on access to medicines in Europe 2014. Available from: http://ec.europa.eu/enterprise/sectors/ healthcare/competitiveness/ process-on-corporate-responsibility/ platform-access/index-en.htm#h2-4
159. Wettermark B, Godman B, Eriksson C, et al. Einführung neuer Arzneimittel in europäische Gesundheitssysteme (Introduction of new medicines into European healthcare systems). GGW 2010; 10(3):24-34
160. Cumming J, Mays N, Daube J. How New Zealand has contained expenditure on drugs. BMJ 2010;340:c2441
161. PHARMAC. Prescription for Pharmacoeconomic Analysis - Methods for cost-utility analysis 2012. Available from: www.pharmac.health.nz/assets/pfpa-final.pdf
162. Wettermark B, Godman B, Andersson K, et al. Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe. Pharmacoeconomics 2008;26(7):537-50
163. Simoens S, De Bruyn K, Miranda J, et al. Measures to enhance ARB prescribing efficiency in Belgium following generic losartan: impact and implications for the future. J Pharmaceutical Health Services Res 2013;4:173-81
164. Jagodzińska-Kalinowska K, Ofierska-Sujkowska G, Matusewicz W. The influence of recommendations related to antineoplastic drugs issued by agency for health technology assessment in poland (AOTM) in 2013 for the reimbursement decisions. Abstract Booklet - HTAi Annual Meeting 2014 2014:122. Available from: www.htai2014.org/temp/201461669967/ HTAI-AbstractVolume-web2.pdf
165. Godman B, Persson M, Miranda J, et al. Changes in the utilization of venlafaxine after the introduction of generics in Sweden. Appl Health Econ Health Policy 2013; 11(4):383-93
166. Efpia. improving patient access to innovative medicines - the framework in which differentiated pricing may offer a solution 2014. Available from: www.efpia. eu/uploads/Modules/Documents/pac- 280214-ai6-a1-differentiated-pricingposition- paper-final.pdf
167. Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev Pharmacoecon Outcomes Res 2012;12(1):125-30
168. Coma A, Zara C, Godman B, et al. Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction. Expert Rev Pharmacoecon Outcomes Res 2009;9(6):569-81
169. Norman C, Zarrinkoub R, Hasselstrom J, et al. Potential savings without compromising the quality of care. Int J Clin Pract 2009;63(9):1320-6
170. Godman B, Campbell S, Suh HS, et al. Ongoing measures to enhance prescribing efficiency across Europe: implications for other countries. J Health Tech Assess 2013;1:27-42